Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

Authors: Yuan Li, Yang Du, Ting Sun, Huadan Xue, Zhengyu Jin, Jie Tian

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model.

Methods

The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment.

Results

The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity.

Conclusion

Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment.
Literature
1.
Maccio A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives [J]. Obes Rev. 2009;10(6):660–70.CrossRefPubMed
2.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
3.
Su M, Huang CX, Dai AP. Immune checkpoint inhibitors: therapeutic tools for breast Cancer[J]. Asian Pac J Cancer Prev. 2016;17(3):905–10.CrossRefPubMed
4.
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med. 2012;366(26):2455–65.CrossRefPubMedPubMedCentral
5.
6.
Bedognetti D, Maccalli C, Bader SB, et al. Checkpoint inhibitors and their application in breast Cancer[J]. Breast Care (Basel). 2016;11(2):108–15.CrossRef
7.
Migali C, Milano M, Trapani D, et al. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond[J]. Ther Adv Med Oncol. 2016;8(5):360–74.CrossRefPubMedPubMedCentral
8.
Nivolumab Doubles Survival for Patients with HNSCC[J]. Cancer Discov. 2016;6(7):F3.CrossRef
9.
Mann JE, Hoesli R, Michmerhuizen NL, et al. Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC[J]. J Cancer. 2017;8(3):332–44.CrossRefPubMedPubMedCentral
10.
Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma[J]. Cancer Res. 2007;67(23):11438–46.CrossRefPubMedPubMedCentral
11.
Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation[J]. J Surg Res. 2009;151(1):115–20.CrossRefPubMed
12.
Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway[J]. J Cell Mol Med. 2010;14(12):2803–15.CrossRefPubMed
13.
Comito G, Segura CP, Taddei ML, et al. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts[J]. Oncotarget. 2016;
14.
Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial[J]. Lancet Oncol. 2014;15(1):114–22.CrossRefPubMed
15.
Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial[J]. Lancet Oncol. 2014;15(9):997–1006.CrossRefPubMed
16.
Jia XH, Du Y, Mao D, et al. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages[J]. Oncotarget. 2015;6(28):26018–28.CrossRefPubMedPubMedCentral
17.
Wang L, Su W, Liu Z, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma[J]. Biomaterials. 2012;33(20):5107–14.CrossRefPubMed
18.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol. 2001;2(3):261–8.CrossRefPubMed
19.
Kitazawa Y, Fujino M, Wang Q, et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses[J]. Transplantation. 2007;83(6):774–82.CrossRefPubMed
20.
Ren HT, Li YM, Wang XJ, et al. PD-1 rs2227982 polymorphism is associated with the decreased risk of breast Cancer in northwest Chinese women: a hospital-based observational study[J]. Medicine (Baltimore). 2016;95(21):e3760.CrossRef
21.
Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study[J]. Ann Oncol. 2016;27(12):2242–50.CrossRefPubMedPubMedCentral
22.
Iwai Y, Hemmi H, Mizenina O, Kuroda S, Suda K, Steinman RM. An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLoS One. 2008;3(6):e2404.CrossRefPubMedPubMedCentral
23.
Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate[J]. Blood. 2003;102(6):2229–35.CrossRefPubMed
24.
Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model[J]. Clin Cancer Res. 2004;10(13):4559–67.CrossRefPubMed
Metadata
Title
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
Authors
Yuan Li
Yang Du
Ting Sun
Huadan Xue
Zhengyu Jin
Jie Tian
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4412-8

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Case report

Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

Research article

Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma

Case report

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Study protocol

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Research article

Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis

Research article

GPNMB methylation: a new marker of potentially carcinogenic colon lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits